Interestingly, the sensitivity of different small cell lung cancer (SCLC) cell lines to the ADP-ribosylation inhibitor BMN 673 negatively correlated with the activity of the pro-survival pathway AKT. This evidence concerns the gene AKT1 and small cell lung carcinoma.